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Sodium glucose cotransporter 2 inhibitors and risk of serious 
adverse events: nationwide register based cohort study
Peter Ueda,1 Henrik Svanström,1,2 Mads Melbye,2,3,4 Björn Eliasson,5 Ann-Marie Svensson,6 
Stefan Franzén,6 Soffia Gudbjörnsdottir,5,6 Kristian Hveem,7,8 Christian Jonasson,7,8  
Björn Pasternak1,2
ABSTRACT
OBJECTIVE
To assess the association between the use of sodium 
glucose cotransporter 2 (SGLT2) inhibitors and seven 
serious adverse events of current concern.
DESIGN
Register based cohort study.
SETTING
Sweden and Denmark from July 2013 to December 
2016.
PARTICIPANTS
A propensity score matched cohort of 17 213 new 
users of SGLT2 inhibitors (dapagliflozin, 61%; 
empagliflozin, 38%; canagliflozin, 1%) and 17 213 
new users of the active comparator, glucagon-like 
peptide 1 (GLP1) receptor agonists.
MAIN OUTCOME MEASURES
The primary outcomes were lower limb amputation, 
bone fracture, diabetic ketoacidosis, acute kidney 
injury, serious urinary tract infection, venous 
thromboembolism, and acute pancreatitis, as 
identified from hospital records. Hazard ratios and 
95% confidence intervals were estimated by using Cox 
proportional hazards models.
RESULTS
Use of SGLT2 inhibitors, as compared with GLP1 
receptor agonists, was associated with an increased 
risk of lower limb amputation (incidence rate 2.7 v 
1.1 events per 1000 person years, hazard ratio 2.32, 
95% confidence interval 1.37 to 3.91) and diabetic 
ketoacidosis (1.3 v 0.6, 2.14, 1.01 to 4.52) but not 
with bone fracture (15.4 v 13.9, 1.11, 0.93 to 1.33), 
acute kidney injury (2.3 v 3.2, 0.69, 0.45 to 1.05), 
serious urinary tract infection (5.4 v 6.0, 0.89, 0.67 
to 1.19), venous thromboembolism (4.2 v 4.1, 0.99, 
0.71 to 1.38) or acute pancreatitis (1.3 v 1.2, 1.16, 
0.64 to 2.12).
CONCLUSIONS
In this analysis of nationwide registers from two 
countries, use of SGLT2 inhibitors, as compared 
with GLP1 receptor agonists, was associated with an 
increased risk of lower limb amputation and diabetic 
ketoacidosis, but not with other serious adverse 
events of current concern.
Introduction
Sodium glucose cotransporter 2 (SGLT2) inhibitors 
present a valuable new therapeutic option for the 
treatment of type 2 diabetes, but concerns have 
been raised regarding their safety. In the CANVAS 
Program, patients randomised to the SGLT2 inhibitor 
canagliflozin experienced significantly higher rates 
of lower limb amputation (hazard ratio 1.97, 95% 
confidence interval 1.41 to 2.75) and bone fracture 
(1.26, 1.04 to 1.52) compared with patients receiving 
placebo.1 Case reports to the United States Food and 
Drug Administration’s (FDA) Adverse Event Reporting 
System (FAERS) have indicated that SGLT2 inhibitors 
could cause diabetic ketoacidosis,2 3 acute kidney 
injury,4 5 and serious urinary tract infection.2 SGLT2 
inhibitors increase blood viscosity by inducing mild 
diuresis, which suggests that the risk of venous 
thromboembolism could be increased.6 7 The FDA 
is also investigating reports of acute pancreatitis 
associated with the use of SGLT2 inhibitors.8-10
Completed and ongoing clinical trials are conducted 
in selected populations and are too small to assess 
rare adverse events, whereas analyses of case reports 
have substantial limitations, including a lack of 
denominators and possible reporting bias. Only four 
controlled large scale observational studies have been 
conducted.11-14 Each study investigated one selected 
adverse event and three studies used study designs 
with method limitations,11-13 including immortal time 
bias and lag time bias.15 Therefore, the safety of SGLT2 
inhibitors is still uncertain.
In this register based cohort study of patients from 
routine clinical practice, we used nationwide data 
from Sweden and Denmark to assess whether the 
use of SGLT2 inhibitors, as compared with an active 
comparator (glucagon-like peptide 1 (GLP1) receptor 
agonists), is associated with an increased risk of seven 
serious adverse events of current concern.
Methods
Study design
We conducted a cohort study from July 2013 to 
December 2016, with data from nationwide health and 
administrative registers in Sweden and Denmark. The 
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registers included population registers (vital status, 
demographics), patient registers (comorbidities, 
outcomes), prescription registers (study drugs, 
comedications), Statistics Denmark and Statistics 
Sweden (socioeconomic variables), and the Swedish 
National Diabetes Register (glycated haemoglobin level, 
blood pressure, albuminuria, estimated glomerular 
filtration rate, body mass index, and smoking status), 
which are described in the supplementary materials.
We used an active comparator new-user study 
design and controlled for a wide range of potential 
confounders (patient characteristics that might be 
associated with both the outcome and the decision to 
initiate a drug) through a non-parsimonious propensity 
score model to minimise the risk of bias, including 
confounding by indication.16 We used GLP1 receptor 
agonists as the active comparator because of important 
shared features with SGLT2 inhibitors, including use 
in similar clinical situations (ie, as second line or 
third line diabetes drugs, with both drug classes likely 
considered for patients at high cardiovascular risk) and 
similar temporal trends of use in the two countries,1 17-21 
but no known associations with the outcomes 
investigated in this study.
Study population
We included all patients in the two countries, aged 35 
or over, who filled their first prescription for either an 
SGLT2 inhibitor or a GLP1 receptor agonist during the 
study period; the date of filling the first prescription 
constituted cohort entry. We excluded patients who 
had previously filled prescriptions for any of the study 
drugs; had no hospital contact or use of prescription 
drugs in the previous year; had dialysis or renal 
transplantation, endstage illness, drug misuse, or 
severe pancreatic disorders; or had a hospital stay 
for any reason in the 30 days before cohort entry 
(supplementary materials, table 1).
Patients were considered exposed to the study drug 
if prescriptions were refilled before the estimated end 
date of the most recent prescription. We included a 
grace period of 90 days to account for irregular drug 
intake and to capture events that occured shortly after 
treatment cessation (supplementary materials, table 2).
We estimated propensity scores by using 
logistic regression for the probability of starting 
an SGLT2 inhibitor conditional on the status of 66 
covariates, defined and selected a priori, including 
sociodemographic characteristics, comorbidities, 
comedications, and healthcare utilisation, as current at 
cohort entry in Sweden and Denmark (supplementary 
materials, table 3). The nationwide registers provided 
complete information on disease history (for the 
previous 10 years) and prescription drug use in each 
country before cohort entry. Missing data on place of 
birth (<1%), civil status (<1%), and education (3%) 
were handled with use of missing categories.22
We matched SGLT2 inhibitor and GLP1 receptor 
agonist users (1:1 ratio, by country) according to 
propensity score, by using the nearest neighbour 
matching algorithm (caliper width 0.2 of the standard 
deviation of the logit score).23 24 Analyses were 
performed in a pooled dataset of the two countries.
Outcome measures
The primary outcome measures were lower limb 
amputation, bone fracture, diabetic ketoacidosis, 
acute kidney injury, serious urinary tract infection, 
venous thromboembolism, and acute pancreatitis, 
as captured from the patient registers. We also 
conducted analyses restricted to toe or metatarsal 
amputation and to major osteoporotic fracture as 
additional outcomes. Supplementary materials, table 
4 shows outcome definitions according to ICD-10 
(international classification of diseases, 10th edition) 
codes and procedure codes. Diagnoses recorded in 
Scandinavian health registers generally have high 
sensitivity and positive predictive value,25 26 although 
validation studies have only been conducted for some 
of the outcomes in the present study. Supplementary 
materials, table 5 shows validation studies in the 
national patient registers of diagnostic and procedure 
codes related to those used in our study.
Statistical analyses
Patients were followed from cohort entry to treatment 
cessation, crossover to the other study drug (ie, 
initiation of GLP1 receptor agonists among SGLT2 
inhibitor users and vice versa), the outcome event, 
death, emigration, or the end of the study period (31 
December 2016). We used Cox proportional hazards 
regression to calculate hazard ratios, analysing each 
outcome independently. The absolute risk difference 
was calculated as hazard ratio−1 multiplied by the rate 
in the comparator group.
We performed subgroup analyses for all outcomes 
by country, sex, age group, and history of major 
cardiovascular disease (supplementary materials, 
table 6). In additional analyses of diabetic ketoacidosis 
and acute kidney injury, we truncated follow-up at 
six months as reports to FAERS indicate that these 
events can occur shortly after treatment initiation.2-4 
For diabetic ketoacidosis and lower limb amputation, 
we also performed a subgroup analysis according to 
insulin treatment status at baseline and according 
to history of peripheral artery disease or lower limb 
amputation, respectively (supplementary materials, 
table 7).
For all outcomes, we conducted four sensitivity 
analyses. Firstly, we used an intention-to-treat 
exposure definition. In this analysis, patients were 
considered exposed to the study drug throughout 
follow-up regardless of treatment cessation or 
crossover to the other study drug. Secondly, we used 
an additionally adjusted model. In this analysis, for 
the propensity score-matched cohort in Sweden, we 
adjusted the Cox models for additional covariates 
which provided information about disease severity and 
comorbidities related to diabetes, including glycated 
haemoglobin level, blood pressure, albuminuria, 
estimated glomerular filtration rate, body mass 
index, and smoking status (supplementary materials, 
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table 8). Given the proportion of missing data for 
these variables (supplementary materials, table 8), 
we used multiple imputation (Markov chain Monte 
Carlo method) to handle missing data27; analyses 
were conducted by using 10 imputed datasets which 
were combined. Thirdly, we used a grace period of 
30 days in the definition of current use of the study 
drug. Finally, we adjusted the models for country. We 
performed additional sensitivity analyses for bone 
fracture, using an outcome definition only including 
fractures that led to hospital stays, and excluding 
users of thiazolidinediones as these drugs have been 
associated with an increased risk of fracture.28 We 
performed additional sensitivity analysis for acute 
pancreatitis, excluding users of dipeptidyl peptidase 
4 (DPP4) inhibitors because these drugs have been 
associated with acute pancreatitis.29 We performed the 
analysis with SAS version 9.4 software.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for recruitment, design, 
or implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
There are no plans to disseminate the results of the 
research to study participants or the relevant patient 
community.
Results
Study population
Figure 1 shows that we identified 21 008 new users 
of SGLT2 inhibitors and 27 278 new users of GLP1 
receptor agonists who fulfilled the criteria for study 
eligibility. Table 1 shows that, compared with GLP1 
receptor agonist users, SGLT2 inhibitor users were 
older, more likely to be men and to use DPP4 inhibitors 
at baseline, and less likely to have an obesity diagnosis 
and to use insulin at baseline. Figure 1 and table 1 
show that after 1:1 propensity score matching, 34 426 
patients (17 213 in each group) were included in the 
study cohort; the two groups were well balanced on all 
baseline characteristics. Of the SGLT2 inhibitor users, 
61% used dapagliflozin, 38% empagliflozin, and 1% 
canagliflozin. Patient characteristics before and after 
propensity score matching for each country separately 
are shown in supplementary materials, tables 9 and 
10. In the analyses of the seven primary outcome 
measures, median follow-up time in the cohort ranged 
between 270 and 274 days (supplementary materials, 
table 11).
Primary outcomes
Table 2 shows the results of the primary outcome 
analyses. Use of SGLT2 inhibitors, as compared 
with GLP1 receptor agonists, was associated with 
an increased risk of lower limb amputation (hazard 
ratio 2.32, 95% confidence interval 1.37 to 3.91) and 
diabetic ketoacidosis (2.14, 1.01 to 4.52) but not with 
bone fracture (1.11, 0.93 to 1.33), acute kidney injury 
(0.69, 0.45 to 1.05), serious urinary tract infection 
(0.89, 0.67 to 1.19), venous thromboembolism (0.99, 
0.71to 1.38), or acute pancreatitis (1.16, 0.64 to 2.12).
Additional outcomes
The hazard ratio for use of SGLT2 inhibitors versus 
GLP1 receptor agonists was 1.55 (95% confidence 
interval 0.87 to 2.77) for toe or metatarsal amputation 
and 1.05 (0.80 to 1.39) for major osteoporotic bone 
fracture (supplementary materials, table 12).
Subgroup and additional analyses
Figure 2 shows the results of the subgroup analyses. 
For each outcome, hazard ratios in analyses by 
country, sex, age group, and history of cardiovascular 
disease were similar to those observed in the primary 
analyses, although several of these subgroup analyses 
were based on a limited number of events. Hazard 
ratios were also similar in the analysis of diabetic 
ketoacidosis according to insulin treatment status and 
in the analysis of lower limb amputation according 
to history of peripheral artery disease or lower limb 
amputation. Hazard ratios in the additional analyses of 
diabetic ketoacidosis and acute kidney injury in which 
follow-up was truncated at six months after treatment 
initiation were similar to those in the primary analyses 
(supplementary materials, table 14).
Sensitivity analyses
Figure 3 shows the results of the sensitivity analyses. 
Hazard ratios were similar to those in the primary 
analyses when using an exposure definition on 
intention-to-treat basis, a grace period of 30 days in 
the definition of current use of the study drug, and 
when adjusting the models for country. In the Swedish 
cohort (baseline characteristics in supplementary 
materials, table 15), additional adjustment of the 
models for glycated haemoglobin, blood pressure, 
albuminuria, estimated glomerular filtration rate, body 
mass index, and smoking status did not materially 
affect the findings. In the analysis of bone fracture, 
hazard ratios were not affected by the exclusion of 
recent users of thiazolidinediones or by the use of an 
outcome definition that only included fractures leading 
to hospital stays. In the analysis of acute pancreatitis, 
hazard ratios were not affected by the exclusion of 
recent users of DPP4 inhibitors.
Discussion
Using nationwide registers in two countries, we 
examined the risk of serious adverse events associated 
with the use of SGLT2 inhibitors. As compared with 
GLP1 receptor agonists, SGLT2 inhibitor use was 
associated with twofold increases in the risk of both 
lower limb amputation and diabetic ketoacidosis, 
but no noticeable increase in risk was observed for 
the other investigated adverse events. The findings 
should be interpreted in the context of limitations of 
observational studies and the uncertainty of the effect 
estimates. Based on the upper limit of the confidence 
interval, our findings are inconsistent with a relative 
risk increase of more than 33% for bone fracture, 5% 
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for acute kidney injury, 19% for serious urinary tract 
infection, 38% for venous thromboembolism, and 
112% for acute pancreatitis.
The twofold increase in risk of lower limb 
amputation associated with the use of SGLT2 inhibitors 
observed in our study is in line with the findings from 
the CANVAS Program, which randomised patients 
with high cardiovascular risk to canagliflozin or 
placebo.1 Importantly, our results were consistent 
in patients with and without cardiovascular disease 
and with and without peripheral arterial disease 
or previous amputation; the event rates, however, 
were substantially higher in the subgroups with 
such history. A pooled analysis of clinical trials of 
dapagliflozin was underpowered to assess lower limb 
amputations,30 and no imbalance in this outcome in 
patients receiving empagliflozin versus placebo was 
observed in the EMPA-REG OUTCOME trial.31 Whether 
the increase in lower limb amputations is a class effect 
for SGLT2 inhibitors, or specific to individual drugs, 
needs further study.
In our study, the use of SGLT2 inhibitors was not 
associated with the risk of bone fracture. Increased 
risk of fractures in patients using canagliflozin was 
observed in the CANVAS Program but not in the other 
trials of canagliflozin.1 32 A meta-analysis of clinical 
trials revealed no imbalance in fracture rates between 
those treated with empagliflozin versus placebo.33 
Falls owing to volume depletion has been suggested 
as an underlying mechanism for fractures during use 
of SGLT2 inhibitors, but it has also been suggested 
that the drugs affect bone metabolism, as indicated 
by decreased hip bone mineral density after treatment 
with canagliflozin.34 However, in analyses restricted to 
osteoporotic fractures, our results remained similar.
The twofold increased risk of diabetic ketoacidosis 
observed in our study is in accordance with an 
analysis of insurance claims in the US, which showed 
an increase in risk that was of similar magnitude, 
comparing SGLT2 inhibitors with DPP4 inhibitors.14 
Analyses of FEARS data showed higher spontaneous 
reporting rates of diabetic ketoacidosis in SGLT2 
inhibitor users than in DPP4 inhibitor users,3 and 
rates of this adverse event were numerically higher 
among those receiving active treatment in the 
CANVAS Program (0.6 v 0.3 events per 1000 person 
years),1 and in a meta-analysis of clinical trials of 
SGLT2 inhibitors (odds ratio 1.96, 95% confidence 
interval 0.77 to 4.98).35 In addition, higher rates of 
diabetic ketoacidosis have been observed among 
those receiving SGLT2 inhibitors in trials that include 
patients with type 1 diabetes.36 37 Viewed together, 
a relatively coherent picture of an increased risk 
of diabetic ketoacidosis associated with the use of 
SGLT2 inhibitors has emerged, although the absolute 
risk increase seems small.
Reports to FAERS and trials showing a transient 
decrease in glomerular filtration rate after initiation 
of SGLT2 inhibitors have given rise to the concern that 
SGLT2 inhibitors might lead to acute kidney injury.4 5 30 38 
In our study, we found no such association; these 
findings are in line with those from meta-analyses 
of trials of SGLT2 inhibitors,30 33 35 the EMPA-REG 
OUTCOME trial,38 and the CANVAS Program where 
rates of acute kidney injury were similar or numerically 
lower among patients randomized to SGLT2 inhibitors.1
We found no association between the use of SGLT2 
inhibitors and the risk of serious urinary tract infection. 
Whereas reports to FAERS and an imbalance in the 
proportion of patients experiencing urosepsis in the 
EMPA-REG OUTCOME trial (0.4% empagliflozin v 0.1% 
placebo) indicated that SGLT2 inhibitors can lead to 
serious urinary tract infections,2 18 such associations 
were not observed in the CANVAS Program and in a 
meta-analysis of empagliflozin trials.1 33
We found no increase in the risk of venous 
thromboembolism associated with the use of SGLT2 
inhibitors. It has been speculated that SGLT2 inhibitors 
might increase the risk of venous thromboembolism by 
increasing blood viscosity.6 7 A meta-analysis of clinical 
trials, including data from regulatory submissions, 
showed a hazard ratio of 1.54 (95% confidence interval 
0.63 to 3.79) for venous thromboembolism in patients 
receiving active treatment versus placebo,6 but there 
was no imbalance in event rates in the subsequently 
presented CANVAS Program or in meta-analyses of 
SGLT2 inhibitor trials.1 30 33 35
Reports to FAERS have prompted the FDA to 
investigate the risk of acute pancreatitis associated 
with use of SGLT2 inhibitors.8-10 Clinical trials have 
been too small to assess this potential adverse event. 
We found no association between the use of SGLT2 
inhibitors and acute pancreatitis.
Propensity score estimation and 1:1 matching
Excluded*
Previous use of SGLT2 inhibitors
Dialysis or renal transplantation
Endstage illness
Drug misuse
Severe pancreatic disorder
Hospital stay in previous 30 days
Use of liraglutide with obesity indication
No hospital contact and no use of
  prescription drugs in previous year
2262
83
290
309
224
1172
12
66
New users of GLP1 receptor agonists
4192
Excluded*
Previous use of GLP1 receptor agonists
Dialysis or renal transplantation
Endstage illness
Drug misuse
Severe pancreatic disorder
Hospital stay in previous 30 days
Use of liraglutide with obesity indication
No hospital contact and no use of
  prescription drugs in previous year
10 994
28
237
270
345
1035
3
55
31 470
New users of SGLT2 inhibitors
33 380
12 372
Were not matched
New users of SGLT2 inhibitors
New users of GLP1 receptor agonists
3795
10 065
13 860
Patients included in matched cohort
New users of SGLT2 inhibitors
New users of GLP1 receptor agonists
17 213
17 213
34 426
New users of GLP1 receptor agonists eligible for inclusion
27 278
New users of SGLT2 inhibitors eligible for inclusion
21 008
Fig 1 | Flowchart of patient inclusion in the study cohort. SGLT2=sodium glucose 
cotransporter 2; GLP1=glucagon-like peptide 1. *A patient could be excluded for more 
than one reason.
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Characteristic 
Before After
SGLT2 inhibitors GLP1 receptor agonists SGLT2 inhibitors GLP1 receptor agonists
No of patients 21 008 27 278 17 213 17 213
Men 13 113 (62) 15 712 (58) 10 482 (61) 10 449 (61)
Mean (SD) age (years) 62 (10) 60 (11) 61 (10) 61 (10)
SGLT2 inhibitor*:
 Dapagliflozin 12 821 (61) NA 10 454 (61) NA
 Empagliflozin 7864 (37) NA 6506 (38) NA
 Canagliflozin 324 (2) NA 254 (1) NA
Country:
 Sweden 11 891 (57) 17 783 (65) 10 512 (61) 10 512 (61)
 Denmark 9117 (43) 9495 (35) 6701 (39) 6701 (39)
Place of birth:
 Scandinavia 17 242 (82) 23 614 (87) 14 607 (85) 14 556 (85)
 Rest of Europe 1671 (8) 1677 (6) 1184 (7) 1205 (7)
 Outside Europe 2052 (10) 1950 (7) 1399 (8) 1426 (8)
 Missing 43 (<1) 37 (<1) 23 (<1) 26 (<1)
Civil status:
 Married or living with partner† 12 172 (58) 15 130 (55) 9819 (57) 9823 (57)
 Single 8778 (42) 12 088 (44) 7348 (43) 7343 (43)
 Missing 58 (<1) 60 (<1) 46 (<1) 47 (<1)
Education:
 Primary school, secondary school, or vocational training 16 518 (79) 21 264 (78) 13 509 (78) 13 500 (78)
 Short tertiary education 1447 (7) 2157 (8) 1253 (7) 1278 (7)
 Medium or long tertiary education 2495 (12) 3326 (12) 2064 (12) 2048 (12)
 Missing 548 (3) 531 (2) 387 (2) 387 (2)
Year of cohort entry‡:
 2013 1005 (5) 2845 (10) 833 (5) 1746 (10)
 2014 3648 (17) 6434 (24) 3034 (18) 4009 (23)
 2015 6268 (30) 8544 (31) 5161 (30) 5387 (31)
 2016 10 087 (48) 9455 (35) 8185 (48) 6071 (35)
Comorbidities:
 Acute coronary syndrome 1608 (8) 2070 (8) 1300 (8) 1316 (8)
 Other ischaemic heart disease 3468 (17) 4478 (16) 2786 (16) 2794 (16)
 Heart failure or cardiomyopathy 1195 (6) 1881 (7) 1026 (6) 1058 (6)
 Valve disorders 402 (2) 563 (2) 326 (2) 332 (2)
 Stroke 836 (4) 1114 (4) 679 (4) 655 (4)
 Other cerebrovascular disease 918 (4) 1274 (5) 757 (4) 733 (4)
 Atrial fibrillation 1462 (7) 2043 (7) 1222 (7) 1207 (7)
 Other arrhythmia 834 (4) 1109 (4) 673 (4) 687 (4)
 Coronary revascularisation in the past year 282 (1) 334 (1) 230 (1) 219 (1)
 Other cardiac surgery or invasive procedure in the past year 107 (1) 151 (1) 86 (<1) 85 (<1)
 Chronic obstructive pulmonary disease 662 (3) 1136 (4) 586 (3) 559 (3)
 Other lung disease 1298 (6) 2257 (8) 1175 (7) 1160 (7)
 Venous thromboembolism 495 (2) 809 (3) 440 (3) 445 (3)
 Cancer 1433 (7) 1884 (7) 1152 (7) 1175 (7)
 Liver disease 420 (2) 609 (2) 349 (2) 376 (2)
 Rheumatic disease 598 (3) 870 (3) 499 (3) 498 (3)
 Psychiatric disorder 1914 (9) 3279 (12) 1705 (10) 1729 (10)
 Fracture in the past year 326 (2) 449 (2) 267 (2) 268 (2)
 Acute pancreatitis 198 (1) 234 (1) 156 (1) 142 (1)
 Serious urinary tract infection 405 (2) 716 (3) 361 (2) 341 (2)
 Lower limb amputation 34 (<1) 34 (<1) 27 (<1) 23 (<1)
 Arterial disease 1244 (6) 1762 (6) 1035 (6) 1049 (6)
 Renal disease 755 (4) 1726 (6) 708 (4) 735 (4)
 Obesity§ 2742 (13) 6197 (23) 2634 (15) 2726 (16)
 Diabetic eye complications 2605 (12) 4403 (16) 2274 (13) 2315 (13)
 Diabetic ketoacidosis 34 (<1) 68 (<1) 29 (<1) 30 (<1)
 Diabetes, other complications 3777 (18) 6366 (23) 3252 (19) 3251 (19)
Hospital stays in the past year for:
 Cardiovascular causes 809 (4) 1160 (4) 682 (4) 672 (4)
 Type 2 diabetes 163 (1) 369 (1) 145 (1) 134 (1)
 Other causes 2372 (11) 3596 (13) 2001 (12) 2020 (12)
Outpatient visits in the past year for:
 Cardiovascular causes 1701 (8) 2429 (9) 1433 (8) 1395 (8)
 Type 2 diabetes 3364 (16) 6235 (23) 3054 (18) 3104 (18)
 Other causes 10 858 (52) 15 310 (56) 9091 (53) 9077 (53)
Table 1 | Baseline characteristics of users of sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists, 
before and after propensity score matching. Values are numbers (percentages) unless stated otherwise
(Continued)
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Strengths and weaknesses in relation to other 
studies
Using nationwide registers to include data from a large 
number of patients seen in routine clinical practice 
and implementing a controlled study design that 
sought to limit the risk of different sources of bias, our 
study substantially expands on current knowledge 
regarding the safety of SGLT2 inhibitors and quantifies 
the risk of serious adverse events potentially linked 
to the drug class. To date, four controlled large scale 
observational studies, each investigating one selected 
outcome (lower limb amputation and diabetic 
Characteristic 
Before After
SGLT2 inhibitors GLP1 receptor agonists SGLT2 inhibitors GLP1 receptor agonists
Diabetes drugs used in the past six months:
 Metformin 17 203 (82) 20 790 (76) 13 793 (80) 13 830 (80)
 Sulphonylureas 4957 (24) 5513 (20) 3937 (23) 3955 (23)
 DPP4 inhibitors 8315 (40) 7681 (28) 5948 (35) 6007 (35)
 Insulin, fast acting 2796 (13) 6824 (25) 2774 (16) 2836 (16)
 Insulin, intermediate and long acting 5105 (24) 11 818 (43) 5063 (29) 5050 (29)
 Other antidiabetics (glitazones, glinides, acarbose) 825 (4) 945 (3) 646 (4) 653 (4)
 No diabetes drug 1038 (5) 1522 (6) 942 (5) 905 (5)
Time (years) since first diabetes drug:
 <1 1648 (8) 2405 (9) 1480 (9) 1427 (8)
 1-2 2463 (12) 3069 (11) 2117 (12) 2074 (12)
 3-4 2943 (14) 3599 (13) 2473 (14) 2448 (14)
 5-6 3173 (15) 3765 (14) 2529 (15) 2582 (15)
 ≥7 10 781 (51) 14 440 (53) 8614 (50) 8682 (50)
Other drugs used in the past year:
 ARB or ACE-I 14 402 (69) 19 059 (70) 11 928 (69) 11 944 (69)
 Calcium channel blocker 6729 (32) 9262 (34) 5619 (33) 5611 (33)
 Loop diuretic 2463 (12) 4722 (17) 2264 (13) 2308 (13)
 Other diuretic 3558 (17) 5231 (19) 3058 (18) 3043 (18)
 Beta blocker 7414 (35) 10 196 (37) 6231 (36) 6224 (36)
 Digoxin 454 (2) 619 (2) 381 (2) 377 (2)
 Nitrate 1505 (7) 1939 (7) 1212 (7) 1211 (7)
 Platelet inhibitors 7447 (35) 9353 (34) 5937 (34) 5964 (35)
 Anticoagulant 1470 (7) 2132 (8) 1237 (7) 1240 (7)
 Lipid lowering drug 15 046 (72) 19 374 (71) 12 273 (71) 12 261 (71)
 Antidepressant 3139 (15) 5206 (19) 2841 (17) 2855 (17)
 Antipsychotic 701 (3) 989 (4) 609 (4) 584 (3)
 Anxiolytic, hypnotic, or sedative 3154 (15) 4618 (17) 2711 (16) 2728 (16)
 Beta 2 agonist inhalant 1725 (8) 2887 (11) 1538 (9) 1522 (9)
 Anticholinergic inhalant 538 (3) 854 (3) 473 (3) 469 (3)
 Glucocorticoid inhalant 1819 (9) 2964 (11) 1618 (9) 1602 (9)
 Oral glucocorticoid 1365 (6) 2039 (7) 1170 (7) 1123 (7)
 Non-steroidal anti-inflammatory drug 4828 (23) 6544 (24) 4029 (23) 4056 (24)
 Opioid 3474 (17) 5384 (20) 2982 (17) 2989 (17)
Number of drugs used in the past year:
 0-4 2620 (12) 2515 (9) 1944 (11) 1932 (11)
 5-9 8972 (43) 10 046 (37) 7046 (41) 7096 (41)
 10-14 5995 (29) 8360 (31) 5102 (30) 5090 (30)
 ≥15 3421 (16) 6357 (23) 3121 (18) 3095 (18)
DDP4=dipeptidyl peptidase 4; ARB=angiotensin receptor blocker; ACE-I=angiotensin converting enzyme inhibitor; NA=not applicable.
*One patient received both dapagliflozin and empagliflozin at cohort entry.
†Including married or living with partner in Denmark and married in Sweden.
‡Not included in propensity score.
§Diagnosis of obesity in secondary care.
Table 2 | Primary outcome analyses of association between use of sodium glucose cotransporter 2 (SGLT2) inhibitors compared with glucagon-like 
peptide 1 (GLP1) receptor agonists and risk of serious adverse events
Adverse event
SGLT2 inhibitors (n=17 213) GLP1 receptor agonists (n=17 213)
Hazard ratio (95% CI) Absolute risk difference (95% CI)No of events
No of events per 
1000 patient years No of events
No of events per 
1000 patient years
Lower limb amputation 40 2.7 22 1.1 2.32 (1.37 to 3.91) 1.5 (0.4 to 3.3)
Bone fracture 228 15.4 263 13.9 1.11 (0.93 to 1.33) 1.5 (−1.0 to 4.6)
Diabetic ketoacidosis 19 1.3 11 0.6 2.14 (1.01 to 4.52) 0.7 (0.0 to 2.0)
Acute kidney injury 34 2.3 62 3.2 0.69 (0.45 to 1.05) −1.0 (−1.8 to 0.2)
Serious urinary tract infection 80 5.4 114 6.0 0.89 (0.67 to 1.19) −0.7 (−2.0 to 1.1)
Venous thromboembolism 63 4.2 79 4.1 0.99 (0.71 to 1.38) 0.0 (−1.2 to 1.6)
Acute pancreatitis 20 1.3 23 1.2 1.16 (0.64 to 2.12) 0.2 (−0.4 to 1.3)
Table 1 | Continued
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Lower limb amputation
Country
  Sweden
  Denmark
Sex
  Female
  Male
Age (years)
  35 to <65
  ≥65
Cardiovascular disease
  No
  Yes
Peripheral artery disease or lower
limb amputation
  No
 Yes
Bone fracture
Country
  Sweden
  Denmark
Sex
  Female
  Male
Age (years)
  35 to <65
  ≥65
Cardiovascular disease
  No
  Yes
Diabetic ketoacidosis
Country
  Sweden
  Denmark
Sex
  Female
  Male
Age (years)
  35 to <65
  ≥65
Cardiovascular disease
  No
  Yes
Insulin
  No
  Yes
Acute kidney injury
Country
  Sweden
  Denmark
Sex
  Female
  Male
Age (years)
  35 to <65
  ≥65
Cardiovascular disease
  No
  Yes
2.70 (1.17 to 6.22)
2.18 (1.11 to 4.30)
5.13 (1.08 to 24.3)
2.02 (1.15 to 3.54)
2.88 (1.32 to 6.31)
1.96 (0.96 to 4.00)
2.12 (0.96 to 4.69)
2.59 (1.29 to 5.22)
2.48 (1.14 to 5.40)
2.13 (1.05 to 4.32)
1.06 (0.84 to 1.34)
1.20 (0.91 to 1.57)
1.19 (0.93 to 1.53)
1.04 (0.81 to 1.34)
1.15 (0.90 to 1.47)
1.06 (0.82 to 1.38)
1.17 (0.95 to 1.44)
0.96 (0.67 to 1.38)
2.33 (0.87 to 6.22)
1.90 (0.59 to 6.11)
4.64 (0.98 to 21.9)
1.55 (0.64 to 3.77)
3.31 (1.17 to 9.34)
1.18 (0.38 to 3.69)
2.24 (0.98 to 5.09)
1.60 (0.27 to 9.59)
1.71 (0.52 to 5.68)
2.45 (0.93 to 6.47)
0.62 (0.38 to 1.01)
0.90 (0.39 to 2.08)
0.69 (0.36 to 1.33)
0.69 (0.40 to 1.19)
0.62 (0.29 to 1.31)
0.74 (0.44 to 1.22)
0.57 (0.33 to 0.97)
1.03 (0.51 to 2.09)
0.1 0.5 21 10
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
18/2
22/3.8
8/1.4
32/3.5
21/2.3
19/3.3
16/1.3
24/9
18/1.3
22/30.2
131/14.4
97/16.9
119/20.9
109/11.9
123/13.4
105/18.6
177/14.5
51/19.4
12/1.3
7/1.2
8/1.4
11/1.2
13/1.4
6/1
16/1.3
3/1.1
6/0.6
13/2.9
25/2.7
9/1.6
14/2.4
20/2.2
10/1.1
24/4.2
20/1.6
14/5.3
8/0.7
14/1.7
<3*/0.3
20/1.7
9/0.8
13/1.7
10/0.6
12/3.3
10/0.5
12/13.2
148/13.5
115/14.4
132/17.8
131/11.4
137/11.8
126/17.1
192/12.5
71/19.9
6/0.5
5/0.6
<3*/0.3
9/0.8
5/0.4
6/0.8
9/0.6
<3*/0.6
5/0.4
6/1.1
48/4.3
14/1.7
26/3.5
36/3.1
21/1.8
41/5.5
44/2.8
18/5
SGLT2
inhibitors
GLP1 receptor
agonists
No of events/No of events
per 1000 patient years
Serious urinary tract infection
Country
  Sweden
  Denmark
Sex
  Female
  Male
Age (years)
  35 to <65
  ≥65
Cardiovascular disease
  No
  Yes
Venous thromboembolism
Country
  Sweden
  Denmark
Sex
  Female
  Male
Age (years)
  35 to <65
  ≥65
Cardiovascular disease
  No
  Yes
Acute pancreatitis
Country
  Sweden
  Denmark
Sex
  Female
  Male
Age (years)
  35 to <65
  ≥65
Cardiovascular disease
  No
  Yes
0.72 (0.49 to 1.05)
1.21 (0.78 to 1.88)
0.91 (0.58 to 1.41)
0.89 (0.61 to 1.30)
1.20 (0.76 to 1.90)
0.75 (0.52 to 1.10)
0.90 (0.62 to 1.29)
0.93 (0.58 to 1.47)
0.99 (0.65 to 1.52)
0.97 (0.57 to 1.65)
1.22 (0.73 to 2.03)
0.85 (0.55 to 1.33)
1.28 (0.77 to 2.14)
0.83 (0.53 to 1.29)
1.02 (0.69 to 1.51)
0.95 (0.50 to 1.81)
1.44 (0.68 to 3.03)
0.74 (0.25 to 2.18)
2.62 (0.87 to 7.86)
0.78 (0.37 to 1.66)
1.48 (0.72 to 3.05)
0.63 (0.19 to 2.05)
1.09 (0.55 to 2.17)
1.46 (0.42 to 5.10)
0.1 0.5 21 10
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
42/4.6
38/6.6
34/5.9
46/5
36/3.9
44/7.7
49/4
31/11.7
39/4.3
24/4.2
29/5
34/3.7
30/3.2
33/5.8
47/3.8
16/6
15/1.6
5/0.9
9/1.6
11/1.2
16/1.7
4/0.7
15/1.2
5/1.9
70/6.3
44/5.5
49/6.5
65/5.6
37/3.2
77/10.4
69/4.5
45/12.5
47/4.2
32/4
30/4
49/4.2
29/2.5
50/6.7
56/3.6
2/6.4
13/1.2
10/1.2
5/0.7
18/1.5
14/1.2
9/1.2
18/1.2
5/1.4
SGLT2
inhibitors
GLP1 receptor
agonists
No of events/No of events
per 1000 patient years
Fig 2 | Subgroup analyses of serious adverse events among sodium glucose cotransporter 2 (SGLT2) inhibitor users compared with glucagon-like 
peptide 1 (GLP1) receptor agonist users. P values for homogeneity (all >0.05) are shown in supplementary materials, table 13. *Number of events not 
specified for <3 according to regulations on reporting Danish register data.
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ketoacidosis),11-14 have been conducted on SGLT2 
inhibitors and potential adverse events. Three of 
these studies used a design that permitted patients 
with a history of comparator drug use to enter the 
cohort.11-13 Therefore, the studies could suffer from 
compromised confounding control,16 as indicated by 
the imbalance in diabetic drugs at baseline between 
users of SGLT2 inhibitors versus comparators, even 
after propensity score matching. In addition, the 
implementation of a hierarchical selection of SGLT2 
inhibitor treatment episodes in those studies, gives 
rise to immortal time bias in patients initiating an 
SGLT2 inhibitor after having used a comparator 
drug during the study period.11-13 15 Further, lag time 
bias could result from the use of any other glucose 
lowering drug as comparator,15 because some of these 
drugs are typically used at earlier or later stages of 
diabetes than SGLT2 inhibitors.19
We attempted to limit the risk of confounding by 
using a new-user design in which patients had no 
history of either study drug at cohort entry, a non-
parsimonious propensity score and rigorous matching, 
as well as GLP1 receptor agonists as the comparator. 
In sensitivity analyses in Sweden (61% of the overall 
cohort), we also adjusted for glycated haemoglobin 
level, blood pressure, albuminuria, estimated 
glomerular filtration rate, body mass index, and 
smoking status; the consistency of results between 
these analyses and our main analyses indicate that 
confounding owing to these variables was minimal, 
although some of these analyses had few events for 
each variable used for multivariate adjustment.
Limitations
Our study has limitations. Firstly, we performed 
analyses for SGLT2 inhibitors as a drug class; 
dapagliflozin (61%) and empagliflozin (38%) 
were the most common SGLT2 inhibitors in our 
study population and use of canagliflozin was 
rare. The mechanisms underlying the potential 
adverse events associated with SGLT2 inhibitors 
are unknown. Class-wide effects, including volume 
depletion (lower limb amputation,39 bone fracture,32 
diabetic ketoacidosis,40 acute kidney injury,41 and 
venous thromboembolism),6 increased levels of 
phosphate and secondary hyperparathyroidism 
(bone fracture),42 non-insulin dependent glucose 
lowering and increased glucagon levels (diabetic 
ketoacidosis),40 uricosuria (acute kidney injury),41 
and glucosuria (serious urinary tract infection) 
have been suggested.43 However, pharmacologic 
properties and off-target effects specific to individual 
drugs have been described and reduced hip bone 
mineral density has been observed after treatment 
with canagliflozin.34 44 45 Uncertainty regarding 
the potential effects specific to individual SGLT2 
inhibitors remains and assessment of adverse events 
for individual SGLT2 inhibitors remains a topic for 
additional examination. 
Secondly, the number of events in many of the 
subgroup analyses were low, resulting in wide 
confidence intervals. More well powered analyses will 
require further accumulation of clinical data on the use 
of SGLT2 inhibitors. 
Thirdly, we defined drug exposure based on filled 
prescriptions; low adherence might bias the results 
towards the null. 
Fourthly, although diagnoses recorded in 
Scandinavian health registers generally have high 
sensitivity and positive predictive value,25 26 validation 
studies of the outcomes in our study have only been 
performed for venous thromboembolism, acute 
pancreatitis, and certain fractures, infections, and 
amputations.25 26 46 47 Outcome misclassification 
could have introduced bias in our analyses; such 
misclassification is unlikely to be differential in the 
context of this study design and would thus only 
Lower limb amputation
  Intention-to-treat exposure definition
  Additionally adjusted model
  Varied grace period (30 days)
  Adjusted for country
Bone fracture
  Intention-to-treat exposure definition
  Additionally adjusted model
  Varied grace period (30 days)
  Adjusted for country
  Varied outcome definition
  (fracture leading to hospital stay)
  Excluding users of thiazolidinediones
Diabetic ketoacidosis
  Intention-to-treat exposure definition
  Additionally adjusted model
  Varied grace period (30 days)
  Adjusted for country
Acute kidney injury
  Intention-to-treat exposure definition
  Additionally adjusted model
  Varied grace period (30 days)
  Adjusted for country
Serious urinary tract infection
  Intention-to-treat exposure definition
  Additionally adjusted model
  Varied grace period (30 days)
  Adjusted for country
Venous thromboembolism
  Intention-to-treat exposure definition
  Additionally adjusted model
  Varied grace period (30 days)
  Adjusted for country
Acute pancreatitis
  Intention-to-treat exposure definition
  Additionally adjusted model
  Varied grace period (30 days)
  Adjusted for country
  Excluding users of DPP4 inhibitors
1.90 (1.25 to 2.87)
2.79 (1.19 to 6.55)
2.70 (1.41 to 5.17)
2.37 (1.40 to 4.00)
1.07 (0.92 to 1.24)
1.09 (0.86 to 1.39)
1.12 (0.91 to 1.37)
1.11 (0.93 to 1.33)
1.09 (0.78 to 1.51)
1.12 (0.94 to 1.34)
1.95 (1.00 to 3.80)
2.13 (0.79 to 5.78)
1.99 (0.73 to 5.41)
2.14 (1.01 to 4.52)
0.90 (0.63 to 1.27)
0.72 (0.44 to 1.18)
0.73 (0.45 to 1.20)
0.68 (0.45 to 1.03)
1.06 (0.84 to 1.35)
0.81 (0.55 to 1.20)
0.88 (0.64 to 1.22)
0.89 (0.67 to 1.19)
0.99 (0.75 to 1.30)
1.11 (0.72 to 1.71)
0.98 (0.67 to 1.44)
0.99 (0.71 to 1.38)
1.27 (0.76 to 2.13)
1.47 (0.69 to 3.14)
1.35 (0.68 to 2.68)
1.15 (0.63 to 2.10)
1.20 (0.58 to 2.48)
0.1 0.5 21 10
Hazard ratio
(95% CI)
Outcome Hazard ratio
(95% CI)
56/2.9
18/2.0
31/2.6
40/2.7
318/16.4
131/14.4
178/15.3
228/15.4
66/4.4
223/15.2
23/1.2
12/1.3
11/0.9
19/1.3
55/2.8
25/2.7
26/2.2
34/2.3
125/6.4
42/4.6
64/5.5
80/5.4
91/4.6
39/4.3
48/4.1
63/4.2
29/1.5
 15/1.6
17/1.4
20/1.3
14/1.5
38/1.6
8/0.7
13/0.9
22/1.1
373/15.5
148/13.5
193/13.7
263/13.9
79/4.1
256/13.6
14/0.6
6/0.5
6/0.4
11/0.6
76/3.1
48/4.3
42/3.0
62/3.2
147/6.1
70/6.3
87/6.2
114/6.0
115/4.7
47/4.2
58/4.1
79/4.1
29/1.2
13/1.2
16/1.1
23/1.2
16/1.3
SGLT2
inhibitors
GLP1 receptor
agonists
No of events/No of events
per 1000 patient years
Fig 3 | Sensitivity analyses of serious adverse events among sodium glucose 
cotransporter 2 (SGLT2) inhibitor users compared with glucagon-like peptide 1 (GLP1) 
receptor agonist users. DPP4=dipeptidyl peptidase 4.
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introduce bias, if any, towards the null. A study from 
the US showed that diagnostic codes of acute kidney 
injury in administrative databases have high specificity 
although registration of events could be incomplete48; 
the event rates observed in our study should be 
interpreted with caution. 
Finally, residual and unmeasured confounding 
affecting the findings in our study cannot be ruled out.
Conclusion
In this analysis of nationwide registers from two 
countries, SGLT2 inhibitors, as compared with 
GLP1 receptor agonists, were associated with an 
increased risk of lower limb amputations and diabetic 
ketoacidosis, but not with other serious adverse events 
of current concern.
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